Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

 
Madvertise - Successful start in the United States - First campaigns signed with the most prestigious advertising agencies
Madvertise - Successful start in the United States - First campaigns signed with the most prestigious advertising agencies

Press Release

Paris, 22 April 2021 – 6 p.m.

Madvertise (Euronext Growth - FR0010812230 - ALMNG), the European AdTech company specializing in mobile advertising, confirms the successful deployment of

EOS imaging Reports its Full Year 2020 Results and First Quarter 2021 Revenues
EOS imaging Reports its Full Year 2020 Results and First Quarter 2021 Revenues


Regulatory News:



EOS imaging (Euronext, FR0011191766 - EOSI - Eligible PEA - PME) (Paris:EOSI), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and

GenSight Biologics Reports Cash Position as of March 31, 2021 and Provides Operational Update: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg
GenSight Biologics Reports Cash Position as of March 31, 2021 and Provides Operational Update


Regulatory News:



GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies

 
MND : First detachable ropeways system awarded for MND in the United-States of America
MND : First detachable ropeways system awarded for MND in the United-States of America

MND, the French industrial group specializing in ropeway mobility, snowmaking systems, mountain safety and sensational leisure infrastructures, continues to support the development of Waterville

Valbiotis startet Kapitalerhöhung durch Privatplatzierung: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg
Valbiotis startet Kapitalerhöhung durch Privatplatzierung


Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA-PME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von

Valbiotis: Weitgehend erfolgreiche Kapitalerhöhung durch Privatplatzierung in Höhe von 15 Millionen Euro: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg
Valbiotis: Weitgehend erfolgreiche Kapitalerhöhung durch Privatplatzierung in Höhe von 15 Millionen Euro


Regulatorische Nachrichten:



Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA-PME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur

Valbiotis: Largely Successful Capital Increase Through a Private Placement Totaling 15 Million Euros: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg
Valbiotis: Largely Successful Capital Increase Through a Private Placement Totaling 15 Million Euros


Regulatory News:



Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA-PME eligible), a Research & Development company committed to scientific innovation for the treatment and prevention of

 
METABOLIC EXPLORER : METEX : Signature of the Share Purchase Agreement (SPA) for the transfer of 100% of the capital of Ajinomoto Animal Nutrition Europe (AANE).
METABOLIC EXPLORER : METEX : Signature of the Share Purchase Agreement (SPA) for the transfer of 100% of the capital of Ajinomoto Animal Nutrition Europe (AANE).

Signature of the Share Purchase Agreement (SPA) for the transfer of 100% of the capital of Ajinomoto Animal Nutrition Europe (AANE)  

  • Favourable opinion from the employee representative bodies
  • No
Valbiotis Launches a Capital Increase Through a Private Placement: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg
Valbiotis Launches a Capital Increase Through a Private Placement


Regulatory News:



Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA-PME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic

BIOCORP und ROCHE DIABETES CARE FRANCE bringen Mallya auf den Markt – das innovative medizinische Gerät verbessert die Lebensqualität von Diabetes-Patienten: https://mms.businesswire.com/media/20191211005828/en/639213/5/Logo_Biocorp.jpg
BIOCORP und ROCHE DIABETES CARE FRANCE bringen Mallya auf den Markt – das innovative medizinische Gerät verbessert die Lebensqualität von Diabetes-Patienten


Pflichtmitteilung:



BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / PEA/KMU-qualifiziert), ein französisches Unternehmen mit Spezialisierung auf Design, Entwicklung und Herstellung von innovativen

BIOCORP and ROCHE DIABETES CARE FRANCE Launch Mallya, an Innovative Medical Device to Better the Daily Life of Patients With Diabetes: https://mms.businesswire.com/media/20191211005828/en/639213/5/Logo_Biocorp.jpg
BIOCORP and ROCHE DIABETES CARE FRANCE Launch Mallya, an Innovative Medical Device to Better the Daily Life of Patients With Diabetes


Regulatory News:



BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME) , a French company specialized in the design, development and manufacturing of innovative medical devices, and

Valbiotis Reveals Positive TOTUM•854 Preclinical Results in the Prevention of Hypertension at the Annual ESH-ISH Joint Meeting
Valbiotis Reveals Positive TOTUM•854 Preclinical Results in the Prevention of Hypertension at the Annual ESH-ISH Joint Meeting


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210411005016/en/



Figure 1: Effect of TOTUM•854 supplementation on


Valbiotis stellt positive präklinische Ergebnisse von TOTUM•854 bei der Prävention von Bluthochdruck auf der gemeinsamen Jahrestagung der ESH-ISH vor
Valbiotis stellt positive präklinische Ergebnisse von TOTUM•854 bei der Prävention von Bluthochdruck auf der gemeinsamen Jahrestagung der ESH-ISH vor


VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL/PEA/SME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von

Sensorion Announces That a General Meeting of Shareholders Will Be Held Behind Closed Doors on May 18, 2021 Alongside the Publication of Its 2020 Annual Financial Report
Sensorion Announces That a General Meeting of Shareholders Will Be Held Behind Closed Doors on May 18, 2021 Alongside the Publication of Its 2020 Annual Financial Report


Regulatory News:



Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within

Median Technologies Is Releasing Full Year 2020 Financial Results (audited) as Well as Q1 2021 Business Activity Indicators, Showing a Very Strong Growth: https://mms.businesswire.com/media/20200113005579/en/767035/5/Median_strapline.jpg
Median Technologies Is Releasing Full Year 2020 Financial Results (audited) as Well as Q1 2021 Business Activity Indicators, Showing a Very Strong Growth


Regulatory News:



Median Technologies (Paris:ALMDT) (Euronext Growth - ALMDT), whose Board of Directors met on April 6th, 2021 to approve the consolidated financial statements for the financial

 
THERANEXUS : 2020 FULL-YEAR RESULTS AND UPDATE ON THE PROGRESS OF MAIN PROGRAMS
THERANEXUS : 2020 FULL-YEAR RESULTS AND UPDATE ON THE PROGRESS OF MAIN PROGRAMS

Lyon, 7 April 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction

 
MND : Northern Caucasus Resort selects MND to build new ropeways infrastructure
MND : Northern Caucasus Resort selects MND to build new ropeways infrastructure

The Northern Caucasus Resort (NCR), Russia's leading mountain tourism development agency, has chosen the French group MND in an international tender to carry out two major development ropeways

Sensorion Senior Management to Attend Four Conferences in April 2021
Sensorion Senior Management to Attend Four Conferences in April 2021


Regulatory News:



Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within

 
Prismaflex International inform the company is eligible for PEA-PME for 2021/2022
Prismaflex International inform the company is eligible for PEA-PME for 2021/2022

PRISMAFLEX INTERNATIONAL, listed on the Euronext GrowthTH Paris (Code ISIN FR0004044600), confirms its eligibility for the small and mid-caps PEA-PME equity savings vehicle, in accordance with the

Sensorion Publishes Results of Extraordinary General Meeting Resolutions
Sensorion Publishes Results of Extraordinary General Meeting Resolutions


Regulatory News:



Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within

 
Transfer of GECI International shares to the Euronext Growth market
Transfer of GECI International shares to the Euronext Growth market

Transfer of GECI International shares to the Euronext Growth market with effect from March 29, 2021

 

GECI International, the Digital Transformation and Technology Consulting specialist, is

 
MND statement on cyber attack
MND statement on cyber attack

The MND Group (Euronext Growth - FR0011584549 - ALMND) had some of its servers in France and Austria infected by malware on the night of 22-23 March 2021. For security reasons, all of the Group's

VALBIOTIS erhält die ISO 9001-Zertifizierung für seine Aktivitäten im Bereich „Design, Entwicklung und Produktionskontrolle von Lösungen zur Vorbeugung und Bekämpfung von Stoffwechsel- und Herz-Kreislauf-Erkrankungen“ : https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg
VALBIOTIS erhält die ISO 9001-Zertifizierung für seine Aktivitäten im Bereich „Design, Entwicklung und Produktionskontrolle von Lösungen zur Vorbeugung und Bekämpfung von Stoffwechsel- und Herz-Kreislauf-Erkrankungen“


VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL/PEA/SME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von

VALBIOTIS Obtains ISO 9001 Certification for Its Activities in "Design, Development and Production Control of Solutions for Preventing and Combating Metabolic and Cardiovascular Diseases" : https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg
VALBIOTIS Obtains ISO 9001 Certification for Its Activities in "Design, Development and Production Control of Solutions for Preventing and Combating Metabolic and Cardiovascular Diseases"


Regulatory News:



VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / eligible for the PEA/SME), a French Research & Development company committed to scientific innovation for preventing and combating

 
STREAMWIDE : STRONG GROWTH IN 2020 EARNINGS AND MARGINS PROFITABLE GROWTH SET TO CONTINUE IN 2021
STREAMWIDE : STRONG GROWTH IN 2020 EARNINGS AND MARGINS PROFITABLE GROWTH SET TO CONTINUE IN 2021
STRONG GROWTH IN 2020 EARNINGS AND MARGINS PROFITABLE GROWTH SET TO CONTINUE IN 2021      

_ EBITDA: €7.6m (up 68%)

EBIT: €4m (up 233%)

NET INCOME: €3.3m (up 186%)

NET CASH: €6.4m (up